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In beta thalassaemia major transfusions and iron chela-
tion therapy have signiﬁcantly improved the survival and
reduced the morbidity (1, 2). In the 1960’s 80% of
patients had died by the age of 16 (3) and now at least
80% survive beyond the age of 40 yrs (4). This improve-
ment is unique, as no other formerly fatal genetic defect
has shown such a beneﬁt. However, heart complications
still represent signiﬁcant morbidity and remain the lead-
ing cause of mortality in transfusion dependent thalas-
saemia (TM) patients (2). Cardiac dysfunction with
congestive cardiac failure (CCF), arrhythmias and ulti-
mately, premature deaths continue to present. In some
cases this was because of the difﬁculty in accepting the
chelation treatment, which was cumbersome (5), but also
occurred even in some patients who accepted the chela-
tion therapy well (6, 7).
In this review, we present some aspects of the existing
knowledge including our view, acquired of our 30 yrs
experience in following the cardiac course of the disease
in more than 1000 thalassaemic patients. Pathophysiol-
ogy of the heart injury, clinical ﬁndings, diagnosis of
CCF and the global strategies regarding therapeutic
interventions for CCF in TM patients, as well as for
prevention of its onset are herein presented.
Mechanisms of heart injury
Cardiac structure and function in TM are mainly
affected by two competing factors: iron load and
increased cardiac output (CO). The cardiac iron deposi-
tion results in a decrease of left ventricular function. The
anaemia together with marrow expansion leads to vol-
ume overload and increased CO that then demands
increased contractility adding additional stress to the
heart. (Starling’s Law).
The cardiac iron load
Direct iron related injury
Iron overload results principally from the regular blood
transfusions. Patients receive between 0.3 and
0.5 mg⁄kg⁄d of iron through transfusions. The average
daily losses are less than 1 mg in males and 2 mg in
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for effecting body iron reduction. In addition to the
transfused iron, TM patients absorb more iron than nor-
mal individuals. The mechanism of increased absorption
is thought to be related to paradoxical Hepcidin suppres-
sion from the dyserythropoiesis (8–10). In the presence
of excess iron Hepcidin should be elevated to inhibit iron
absorption but the dyserythropoiesis overrides that
effect. Among the different mechanisms in the cellular
pathways of ferrous iron (Fe
2+) membrane L-type cal-
cium channels are signiﬁcantly involved (11). L-type
Ca
2+ channels are high-capacity pathways for ferrous
iron (Fe
2+) uptake into cardiomyocytes in conditions of
iron overload.
Iron is stored in cells, including myocytes, in the form
of ferritin, haemosiderin and free iron. The latter is
referred as the labile cellular iron (LCI) (12). There is a
signiﬁcant ﬂux between the three forms, with haemo-
siderin being the least accessible. The LCI is thought to
be the most accessible to chelation, but it is also the
most toxic form as it stimulates the formation of free
radicals. These result in peroxidative damage of mem-
brane lipids and proteins provoking cellular injury. In
the heart, this leads to impaired function of the mito-
chondrial respiratory chain and is clinically manifested
by reduction of cardiac muscular contractility and CCF
development (13). Furthermore, in the presence of
increased intracellular ferrous iron, the ryanodine sensi-
tive calcium channels of sarcoplasmic reticulum (SR), are
inhibited. This modulates SR calcium release, resulting in
further reduction of cardiac function and arrhythmia
development. The new knowledge on calcium channels
may offer new potential therapeutic interventions for cel-
lular iron reduction and treatment of arrhythmia and
cardiac dysfunction (11, 14, 15).
To date, at least 90 genes that control iron metabolism
have been identiﬁed (16). Due to the possible gene varia-
tions the handling of iron in each individual is expected
to be different. Similarly the action of iron chelators
could be affected and act differently in the individual
patient. It has been shown that TM patients who express
the apo-lipoprotein E4 allele were at greater risk for left
ventricular (LV) dysfunction. Apo E4 is less efﬁcient at
handling oxidative stress (17, 18) when compared to Apo
E2 and Apo E3. Additionally the genetic variations of
the GSTM1 enzyme (Glutathione S-Transferase M1) are
associated with increased cardiac iron deposition in
patients with TM (19). These concepts ﬁt in well with the
wide range of reported different clinical cardiac courses
seen in TM patients who have followed similar life-time,
well accepted treatment (6).
Knowledge derived by recent magnetic resonance
imaging (MRI) studies which also assessed cardiac func-
tion, showed that all patients with reduced LV function
had cardiac iron overload and in many cases this was
severe (20–23). This strongly suggests that in addition to
the damage caused by the accumulated iron, excessive
iron in the myocytes results in greater amounts of LCI
leading to free radical formation that overwhelms the
antioxidant mechanisms and ultimately precipitates car-
diac dysfunction. In the above MRI studies, despite
heavy iron load, many TM patients maintained normal
cardiac function, albeit perhaps temporarily, and this
may be related to their different, intracellular iron
metabolism, in particular their neutralisation of oxidants
as discussed above.
Indirect iron related injury
Infections
Any signiﬁcant infection may precipitate cardiac failure
particularly in the presence of other underlying cardiac
pathology. Immune competence in beta-thalassemia is
impaired (24–27) and patients are more vulnerable to
infections. Furthermore, siderophore bacteria, such as
yersinia and klebsiella, rely on iron for multiplication
and grow well in the microenvironment of TM patients
(26, 27).
Iron overload is considered to be the main etiologic
factor that can disturb the immune balance in favour of
the growth of infectious organisms (25). This may also
be affected by differences in the existing immunogenetic
proﬁle in TM (28) especially with respect to viral infec-
tions. Two severe cardiac complications, pericarditis and
myocarditis, are linked to iron load induced viral infec-
tion susceptibility.
Pericarditis, frequently seen (50%) in TM patients
with poor or no chelation in the past (3), is very rare
today (5%), with the use of chelation therapy (6). Simi-
larly, the reported myocarditis in TM patient with
decreased LV function (29), seems most likely to be
related to iron load. Even though there may be histo-
logical evidence of infections, as demonstrated by lym-
phocytic inﬁltration, recent evidence shows that LV
failure only occurs in the presence of excessive iron
(20–23). Viral myocarditis without iron in the heart
may be rare and may follow similar outcomes to those
of the normal population. Elevated plasma cardiac
enzymes or troponine may be indicative of concomitant
viral myocarditis.
Vascular involvement (afterload)
Systemic arterial involvement in TM, as observed
recently through clinical, functional (30) and anatomical
(31) studies, plays a role in the development of cardiac
dysfunction by affecting heart afterload. Vascular
involvement starts early in life and becomes obvious in
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including elastic tissue abnormalities is expressed in
arteries by thickening and disruption of the elastic lami-
nae and adventitia, followed by calcium deposition. The
injury is suggested to be mediated by the chronic haemo-
lytic state along with the increased labile plasma iron
(LPI). Erythrocyte membrane fragments, haem and free
haemoglobin in addition to free iron, provoke a strong
oxidative stress on endothelium (32). A component of
the vascular dysfunction is due to the reduction of nitric
oxide (NO). There are at least three mechanisms respon-
sible for that effect related to haemolysis; a) Red cell
destruction releases arginase which reduces arginine
levels and its supplementation to the endothelium. b)
Oxyhaemoglobin is transformed to methhaemoglobin
after reacting with NO and converts it to inactive NO
3
i.e. neutralising it and c) Oxidative stress inactivates
endothelial cell enzymes and reduces formation of NO
from the precursor arginine (33).
Similar mechanisms apply also to the pulmonary
artery bed, where vascular contribution together with
coexisting hypercoaguability is considered to be responsi-
ble for increased pulmonary artery resistance (34, 35).
Arrhythmias
The iron induced cardiac toxicity is often complicated
by arrhythmias such as extra atrial and ventricular
beats, paroxysmal atrial tachycardia, ﬂutter or ﬁbrilla-
tion. Life threatening ventricular tachycardia is rare
and often associated with reduced LV function. Short
runs of non-speciﬁc ventricular tachycardia are quite
common and are more common with elevated cardiac
iron. Atrial arrhythmias occur more frequently. These
are more clinically relevant and difﬁcult to treat, but
less speciﬁc for iron toxicity. Some of these arrhyth-
mias can also be triggering factors for CCF or reduced
cardiac function in TM patients without previous
obvious LV dysfunction.
Endocrine abnormalities
Iron toxicity may also indirectly affect heart function by
damaging other organs in varying degrees. The endocrine
abnormalities hypothyroidism and diabetes mellitus can
have a signiﬁcant impact on cardiac function (36). Hypo-
thyroidism can precipitate pericardial effusion, decreased
LV function, bradycardia and increased peripheral vascu-
lar resistance. The onset of diabetes is often associated
with the presentation of cardiac dysfunction. Chronic
hyperglycaemia is an oxidative stress on many organs,
particularly the heart. Hypocalcaemia associated with
occult or overt hypoparathyroidism can precipitate heart
dysfunction.
Medications
Vitamin C has been given to patients in order to enhance
their iron excretion when they are on chelation therapy.
There have been case reports of patients who developed
sudden acute cardiac failure with a fatal outcome that
had been precipitated by the administration of Vitamin
C possibly by releasing free iron that is toxic (37).
Increased CO effect (preload)
Disease related increased CO, resulting in increased
workload on the heart, contributes to the development
of cardiac dysfunction in TM patients. In other chronic
anemias, resting CO increases when Hb levels decline
below 9 g⁄dL (38–41). TM patients, however, even those
well transfused (mean pre transfusion Hb level > 9.5 g⁄dL)
with excellent suppression of marrow activity and with
mean Hb level between transfusions of 11.3 g⁄dL, still
demonstrate some degree of high CO (Cardiac Index
4.3 ± 0.9 L⁄m
2 in TM cf. 3.8 ± 0.8 P < .01 in normal
individuals) (6). It is more obvious in cases were low Hb
levels and tissue hypoxia stimulate compensatory reac-
tions leading to development of peripheral shunts (42).
Liver iron load or viral induced hepatic injury can also
contribute, as cirrhosis can increase CO signiﬁcantly
(43). Furthermore, the presence of elastic ﬁbre degenera-
tion, affecting elastic lamina and adventitia, which render
vessels more susceptible to dilatation by pulse pressure
increase in the context of a hyperkinetic state also
increases the total blood volume (31).
Summary of the mechanisms of heart injury
In TM, the impaired heart from iron overload, is obliged
to maintain a high output through a rigid vascular bed
that results from the abovementioned vascular damage
and is therefore subjected to a continuous state of both
volume and pressure overload rendering the LV more
susceptible to decompensation. Similarly, in TM patients
the coexistence of high CO state and gradually increasing
pulmonary vascular resistance seems to lead to the devel-
opment of pulmonary hypertension (PHT), which readily
precipitates right ventricular (RV) failure (34). Infections,
with a direct or indirect effect also have an impact on
heart function. In well-treated TM patients, the inhibi-
tion of the above mechanisms, result in a considerable
reduction of LV dysfunction incidence, vascular damage,
PHT development and RV failure (44, 45).
Heart pathology
Iron is thought to saturate liver ﬁrstly, and then to
accumulate in other organs. In the heart, it accumulates
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cal conduction system, including the sinoatrial and
atrioventricular nodes (46). In the free wall of the left
ventricle there is more iron concentrated in the epicar-
dial layers than in the endocardial and middle third
(47). From the epicardium, it encroaches upon the peri-
cardium. Such iron deposition raises a possibility that
pericarditis may also have an iron induced chemical
inﬂammatory component and also may cause ﬁbrosis of
the pericardium with or without a history of viral peri-
carditis (Fig. 1). Histology has shown individual myo-
cyte hypertrophy with multiple deposits of brown
granular material within the cytoplasm of the myocytes
(Fig. 2). These granules stain positive with Prussian
blue, conﬁrming heavy myocardial iron deposition.
Interstitial macrophages containing iron are also present
(48). Moreover, the study of cardiac biopsies from TM
patients with light and electron microscopy, as well as
with X-ray microanalysis has revealed the presence of
disrupted myocytes showing loss of myoﬁbers, dense
nuclei, and a variable number of pleomorphic electron
dense granules. These cytoplasmic granules or sidero-
somes consist of iron-containing particles as conﬁrmed
by X-ray microanalysis.
Clinical presentation of cardiac involvement in TM
Cardiac involvement includes heart failure, arrhythmias
and pericarditis. The presentation of pericarditis is simi-
lar to that which occurs in the general population. This
is also the case with arrhythmias.
Heart failure can present at any time after the age of
10 yrs but with optimal treatment, heart failure usually
occurs in the third or fourth decade of life (6). The pre-
sentation can be abrupt, sometimes associated with an
infection or with a slow relentless onset.
Although some patients can present with symptoms of
left-sided heart failure including exertional dyspnoea,
cough and fatigue, followed by ra ˆ les and gallop rhythm
on chest auscultation, it is worth noting that the majority
presents with symptoms and signs of right ventricular
dysfunction. The patients often present to an outpatient
clinic with severe fatigability and abdominal pain, the
latter due to liver distention. The patient may be lying
on the examination couch without dyspnoea. These signs
can easily be misinterpreted as not being symptoms of
cardiac origin (49, 50). The clinical course in this young
population, has often been associated with a gradual
reduction in physical activity, which obscures and delays
the presentation.
However, clinical examination with the patient in a
correct position, will reveal a positive hepatojugular
reﬂex with neck vein distention and a third and fourth
heart sounds. In more severe cases, peripheral oedema
A
B
Figure 1 (A) Operative ﬁeld in a 27 yr old male thalassaemia patient
with a history of recurrent pericarditis and effusive constrictive peri-
carditis at the time of surgery (B) with biopsy from the same
patient demonstrating signiﬁcant pericardial thickening with severe
iron deposition and a small amount of muscle in the left hand corner
which contains iron (Prussian Blue Stain).
Figure 2 Histological features from an autopsy from a 29 yr old male
thalassaemia patient who died of congestive cardiac failure. Histology
shows individual myocyte hypertrophy with multiple deposits of
brown granular material within the cytoplasm of the myocytes. These
granules stain positive with Prussian blue, conﬁrming heavy myo-
cardial iron deposition.
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ance in TM patients should be kept in mind. It results
from the thin iron loaded right ventricle decompensating
earlier (51). Ra ˆ les may be found in cases where there is
also left sided heart failure.
Investigation ﬁndings for CCF
Chest X-ray, shows cardiomegaly but frequently there are
no features of pulmonary congestion. Lung congestion
and pleural effusion may be present as well as a prominent
pulmonary artery in cases with coexisting PHT.
It is unusual for the electrocardiogram (ECG) to be
normal. Wide QRS complex with low voltage, inverted T
waves, non-speciﬁc ST-T changes, Left Ventricular
Hypertrophy, prolonged A-V conduction and arrhyth-
mias are frequently seen.
Doppler echocardiographic study usually shows biven-
tricular dilatation and systolic and diastolic dysfunction.
The variety, however, of the different abovementioned
pathogenetic factors and their degree of contribution to
the cardiac damage, including the different treatment
regimes (lower transfusion schemes, inadequate chela-
tion) lead TM patients, who present with CCF not
always to show uniform cardiac injury. Restrictive
cardiomyopathy-constrictive pericarditis or high cardiac
state Doppler echocardiographic ﬁndings could present
either alone or in combination. The development of
signiﬁcant PHT may accompany the CCF in almost all
the above forms, contributing to the precipitation of
right-sided heart failure. In cases with impaired LV func-
tion, thrombus formation in the apex of the heart may
be present and can lead to the development of stroke
(52) (Fig. 3).
Therapeutic approach to TM patients with CCF
Thalassaemia patients with signs and symptoms of CCF
should be hospitalised and closely monitored. Extensive
laboratory tests should be performed and include:
arterial blood gas,
endocrine proﬁle,




As stated above recent MRI studies have conﬁrmed
that almost all patients with decreased left ventricular
function have severe iron load (20–23). In the acute fail-
ure patients the values of MRI measurements are only
important to determine the degree of iron overload for
future follow-up and can be postponed till after the
patient has improved clinically.
Triggering factors for CCF development such as
arrhythmias, blood volume overload after transfusion,
infections, severe anaemia, should be identiﬁed and
treated. In cases where Yersinia enterocolitica or Klebsiel-
la pneumoniae infection is suspected (53), patients should
be treated even before immunological or bacterial culture
test results are available. If arrhythmias are present, the
least negative inotropic antiarrhythmic agent, amioda-
rone should be infused intravenously (54). In general,
implantable deﬁbrillators are not recommended for the
management of ventricular arrhythmias in TM and the
essential intervention is intensiﬁcation of chelation ther-
apy. However, in rare case of sustained ventricular
tachycardia, later in the clinical progress, an implantable
deﬁbrillator may be necessary.
Daily measurements of body weight, blood pressure
and 24-hrs urine secretion are of paramount importance
in these patients. Frequent monitoring of Hct, Hb, blood
electrolytes, urea, creatinine, glucose, AST, ALT, uric
acid, is also mandatory.
Chelation therapy
Combination of the two iron chelators (deferrioxamine
and deferiprone) seems to maximise the efﬁcacy produc-
ing additive and synergistic effects in iron excretion (55,
56). It seems that each of those two agents chelates iron
from different pools and there is at least an additive
effect when combined treatment is administered (57).
Available evidence now suggests that combined therapy
should be the treatment of choice for patients with estab-
lished cardiac failure. We have reported two cases with
severe CCF who reversed with intensive combination
therapy (58, 59) and we have at least eight more patients
with similar outcome. Two other studies show similar
responses (56, 60). In a recent study with combined
Figure 3 A 30 yr old female thalassaemia patient 2-D four chamber
view with the presence of an apical thrombus.
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cardiac and liver iron and improvement in cardiac func-
tion, the absolute endothelial function was also improved
(45). Furthermore, improvement with glucose tolerance
with the use of combination therapy has been reported
(61, 62) as well as anecdotal reports of improvement in
other endocrine functions. Desferrioxamine should be
administrated at a dose of 60–80 mg⁄kg⁄d intravenously
and deferiprone at a dose of 75–100 mg⁄kg⁄d in three
divided doses. If deferiprone is contraindicated, the
patient should be managed with continuous desferrriox-
amine infusions which usually requires the placement of
an indwelling catheter (63). Continuous desferrioxamine
infusions alone have been shown to improve cardiac
function and salvage patients (64). It seems however, that
the rate of removal of iron with such therapy is much
slower than with combination therapy (45, 63).
Caution should be taken with the 24 h desferrioxamine
infusion to avoid ﬂuid overload especially when intra-
venous antibiotics and antiarrthymic agents are also
indicated.
Transfusions
As CO may be close to normal when Hb level is
‡10 g⁄dL, patients’ Hb concentration should be kept
above 10 g⁄dL by regular blood transfusions. The
patients should only be transfused with one packed red
cell unit no greater than 250 mL with diuretic treatment
as well.
Endocrinopathies
If hypothyroidism is present, a titrated dose of hormone
replacement should be carefully initiated. Diabetes mell-
itus should be regulated with caution. Although hypo-
parathyroidism is generally rare in the thalassaemic
population, it is more often seen in patients with CCF
and shows the typical ECG abnormalities of prolonged
QT interval (36). Calcium is necessary for heart muscle
cell contractility. CCF with the coexistence of low serum
calcium levels is extremely resistant to conventional treat-
ment (65). Serum calcium level should be corrected by
intravenous calcium administration accompanied by oral
vitamin D.
Conventional cardiac disease management
Diuretics, including loop diuretics (e.g. furosemide) and
potassium-sparing agents (e.g. spironolactone), as well as
angiotensin-converting enzyme (ACE)-inhibitors should
be prescribed based on arterial blood pressure. In cases
of persistent normal sinus tachycardia, small doses of
Carvedilol may be given. Digoxin must be prescribed to
patients with atrial ﬁbrillation resistant to conversion.
Diuretics must be prescribed with care for reasons stated
in the following section.
Pulmonary hypertension
If PHT is present, then based on the recent observation
of reduction of NO availability in haemolytic anaemia,
sildenaﬁl should be given in titrated dose, as a ﬁrst
choice. It has been shown to be effective in reducing pul-
monary pressure by NO release (35).
Management of low CO state
Hypoalbuminemia is often present. The combination of
excessive hepatic iron, hepatic viral infections and other
recent infections with the stress of congestion leads to
liver dysfunction, which, in turn, results in reduced albu-
min production. The low serum albumin level could be
masked by diuretic administration. It is important to
note that TM patients with CCF, after strong diuresis, in
combination with hypoalbuminemia are at signiﬁcant
risk of developing reduced renal function or acute renal
failure caused by further reduction in CO due to signiﬁ-
cant preload reduction in the presence of ventricular
dysfunction. Thus, careful albumin administration with
a gradual negative ﬂuid balance by diuretics is necessary.
In case of reduction of renal output, treatment with
intravenous positive inotropic agents (e.g. dopamine-
dobutamine) in a titrated dose alone and⁄or with
haemodialysis should be considered. Though adrenal
insufﬁciency seems to be rare in TM it is possible that
the adrenal reserves are diminished. It may therefore be
valuable in such cases in the ICU setting to give the
patients stress dose steroids empirically. It can also pro-
foundly improve their responses to inotropes.
The above treatment can yield very positive results,
often within a short period of time – even before any sig-
niﬁcant reduction in the cardiac iron load would be
expected. If the patient survives the acute phases of CCF,
treatment should be continued. Patients’ general clinical
condition, echocardiographic studies and MRI T2* mea-
surements could guide subsequent treatment modiﬁca-
tions. Until the ejection fraction approaches normal,
transfusions should be given at 7–10 daily intervals with
reduced amounts of packed cells avoiding volume over-
load. In particular, changing the intravenous desferriox-
amine to daily subcutaneous infusions once the patient is
stabilized, is the ﬁrst step. This allows the patient to be
discharged from hospital. It is essential to note that with
appropriate intervention, particularly intensive chelation
therapy the cardiac function can improve signiﬁcantly
within 6 months. In our own experience, we have seen
that within 2–3 yrs of intensive chelation the heart iron
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completely free of iron. Ultimately, heart function may
revert to normal class I (NYHA) and eventually the
patients can cease their cardiac medications.
Conclusions on CCF in TM
Treatment of iron induced cardiomyopathy requires close
follow-up and signiﬁcant effort until the patient is stabi-
lised. If the patient survives the acute phase, the potential
reversibility of heart injury by heart iron removal prom-
ises an outcome better than that seen in the past in such
situations and may be better than that seen with other
causes of cardiomyopathy with equivalent clinical sever-
ity in the general population (29). However as Hippo-
crates stated, it is better to prevent than to cure. Today
the great challenge in TM patients is to achieve even
better results in preventing heart injury.
Prevention of heart disease
The nowadays accepted treatment has two main
components: transfusion and chelation therapy. Until
recently the latter was only available as parenteral
desferrioxamine.
Hb levels
The main cause of increased CO is low Hb levels,
marrow expansion and their consequences. Transfusion
therapy should reduce the CO, however many patients
on the recommended transfusion regimes (between 9.5
and 10 g⁄dL) still have an increased CO (6). In general
high CO states are well tolerated even with low Hb levels
and in older patients (41). However coupled with other
factors, especially that of transfusion iron overload, it
increases the risk of cardiac impairment.
It is uncertain how the situation in which there are
good transfusion levels but there is still increased CO,
could or should be rectiﬁed. Even though an older study
showed that after 5 months at higher pretransfusion Hb
levels an increased red cell consumption (66) did not
result, higher transfusion levels did not necessarily convey
any particular patient beneﬁt on bone marrow expansion
and increased blood volume (67). Thus, higher pretransfu-
sion Hb levels (mean approx. 10.5 g⁄dL) may be desirable
and long term may reduce the CO and marrow expansion.
However, the target should be to reduce iron rather than
to be too concerned about the marginally elevated CO. In
contrast, in patients who have low pretransfusion Hb
levels, their transfusions should be increased in either
frequency or volume. If the low Hb levels persist despite
adequate transfusions and the red cell consumption is
elevated, splenectomy should be considered (68).
Iron load
The suggested iron chelation regimes available till recently
i.e. with desferrioxamine at 30–40 mg⁄kg body weight per
infusion, 8–10 hrs per infusion 5–7 days per week,
improved survival and reduced morbidity (69). However,
careful iron balance studies have shown that only 52% of
patients on the most commonly used 5 day per week
regime will be in negative iron balance (55). Although des-
ferrioxamine enters the liver rapidly, it enters all other cells
very slowly. These, accompanied by varying compliance
and other factors mentioned in the section on mechanisms
of iron induced heart injury, result in continuing presenta-
tion of cardiac dysfunction and premature cardiac deaths.
Predictive factors of heart injury from iron
For many years, prediction of potential heart iron injury
in TM patient was considered necessary in order to
assess the efﬁcacy of the treatment regimes, particularly
the chelation therapy and to propose any modiﬁcation.
Ferritin levels
The traditional biochemical parameter, serum ferritin,
was relied on universally.
Ferritin levels seen in iron load states mainly represent
a component that has leaked out of cells. It was shown
that ferritin levels had an increasing linear relationship
to the number of transfusions that patients received (70).
With chelation therapy, ferritin levels most often showed
signiﬁcant reduction. Analysed as single measurements
or as mean measurements, they had been regarded as
reasonable indicators of iron load and prognosis. There
have been a number of studies that relate the risk of
death from cardiac disease to ferritin levels that have
been maintained by patients (71). In general, it was con-
sidered that once chelation was commenced, ferritin lev-
els should be maintained below 1500 ng⁄L. Even in a
recent Italian study, deaths in TM were related to higher
ferritin levels at the time of death (2). Overall, persis-
tently high levels of ferritin are associated with poor out-
comes and efforts should be consistently made to
maintain them low. However cardiac deaths still
occurred in patients with satisfactory ferritin levels. In
two recent studies, one which assessed most recent (23)
and one of which assessed highest, lowest, mean 5 yr and
most recent ferritin (22), there was a statistically signiﬁ-
cant relationship of ferritin to MRI assessed cardiac iron
but no predictive value between the two indices.
The limitations of ferritin levels in predicting iron load
and toxicity, include that it is an acute phase reactant
and is reduced in the presence of low ascorbic acid (com-
mon in TM patients) (72). Additionally, free iron as LPI
or LCI could affect cells membranes and therefore result
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ferritin levels. It has been shown that high levels of ferri-
tin may be present even before the tissue iron storage is
excessive. This may be caused by leakage across the cell
membranes because of the iron toxicity (73). In contrast,
intensiﬁed chelation therapy in heavily iron loaded
patients, may rapidly reduce serum ferritin because the
cell membranes are stabilised, while tissue iron, especially
in the heart, remains elevated (74). These hypotheses
may explain some of the limitations.
Liver iron concentrations
In previous post mortem studies, the liver iron quantity
per mg wet weight was approximately tenfold that of the
heart (48) supporting the concept that the rate of accumu-
lation in the liver is greater than in the heart and that heart
is much more sensitive to iron loading. The excessive hepa-
tic iron load may relate to the iron initially loading mostly
in reticulo-endothelial cells and because the majority
(90%) of the body’s R-E system is in the liver (75). Histo-
logical ﬁndings in heavily loaded livers however, show
excessive deposition in parenchymal cells as well.
Liver iron concentrations (LIC) were subsequently
regarded as the gold standard for determining the total
body iron load (76) and as a better indicator of risks than
ferritin. Until recently, the LIC was given great signiﬁ-
cance with respect to the risk of cardiac disease and it
was recommended that levels >12 mg⁄g dry weight were
associated with cardiac death (77). However, one study
has shown that LIC (by biopsy) was not related to cardiac
dysfunction as assessed by stress multiple-gated acquisi-
tion/gated pooled cardiac scan (MUGA) (78), and
another study for LIC estimated by SQUID and Echocar-
diography ﬁndings showed similar lack of relationship (A.
Piga personal communications). These ﬁndings have been
elucidated by recent MRI studies. One did not show sta-
tistical signiﬁcance between LIC and cardiac iron and the
others did, while there was no predictive value between
them (20–23). Therefore, using LIC as a predictor of car-
diac mortality can be misleading. Caution should be exer-
cised, particularly in patients with satisfactory ferritin
levels and LIC as these give a false sense of security and it
is not realised that patients with such levels may have
excessive cardiac iron and need intensiﬁcation of chela-
tion therapy (63). Irrespective of this, major efforts
should be made to maintain low LIC’s because high levels
are potentially dangerous and are associated with other
morbidities such as increased risk of siderophore bacterial
infections, cirrhosis and hepatoma.
With respect to the discrepancy between LIC and car-
diac iron, new knowledge may assist in the understand-
ing of this. The rates of iron accumulation seem to be
different in the liver and the heart (21), while the MRI
studies have shown that when chelation therapy is inten-
siﬁed, the rate of iron clearance between the two organs
seems to be signiﬁcantly different and the liver responds
faster (74). Furthermore, there is also a difference with
respect to the individual chelator’s access to different
iron pools (79).
Echo studies
In TM patients, heart remodelling and function is
affected by many factors as discussed above. Therefore,
structural and functional parameters that can be assessed
by Doppler Echo in normal individuals have less predic-
tive value in TM with respect to the risk of the develop-
ment of cardiac dysfunction. In particularly in patients
with high output state, LV ejection fraction is expected
to be higher than in normal subjects. Thus, for TM
patients, it has been recommended that a normal left
ventricular ejection fraction (LVEF) should be above
60% (80) and the degree of CO increase should be taken
into account when assessing EF in each individual
patient (81).
In general, by knowledge derived mainly from hemo-
chromatosis, it is believed that cardiac diastolic factors in
TM are affected earlier than the systolic ones. TM patients
with normal systolic function have been shown to have
impaired diastolic Doppler indices with restrictive ﬁlling
pattern (82). These latter signs were questioned as to their
predictive value and have been attributed solely to
increased CO (83). Consistently, in a recent study, stan-
dard Doppler left ventricular ﬁlling pattern and pulsed
Doppler tissue imaging parameters in TM were similar to
those seen in conditions of increased preload (84). In con-
trast, in a 5 yr follow-up study which assessed left ventric-
ular diastolic ﬁlling variables by echocardiography, it was
found that these were important predictors of the cardiac
outcome in TM patients (81, 85). Similarly in a recent
study that followed TM patients over a 10 yr period,
under regular constant transfusion-chelation treatment,
some of the diastolic and systolic indices were able to
predict the potential for cardiac risk (81).
Doppler Echo and tissue Doppler studies can only
identify the damage rather than delineating the cause, so
limitation exists also in predicting iron load by Doppler
Echo measurements (86). Structural and functional (sys-
tolic or diastolic indices) relationship to the amount of
iron in the heart assessed by cardiac magnetic resonance
imaging (CMR) was found, but these did not completely
differentiate with speciﬁcity and selectivity the patients at
risk for iron load (87).
Therefore, echo techniques can select a number of
patients who are at risk but they do not identify a large
percentage of those. Doppler Echo remains an impor-
tant monitoring tool for TM patients, particularly if the
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the cardiac disease and should continue to be used. It is
able to perform assessments that cannot be done with
MRI such as pulmonary artery pressures, valvular reﬂux
and diastolic parameters. Doppler Echo remains partic-
ularly valuable in circumstances in which MRI is not
available.
Radionucleide cardiac scans (MUGA)
Resting or combined Resting-Stress radionuclear studies
have been used for assessing left ventricular LV function
in TM (88, 89). Estimation of systolic function was more
accurate than that assessed by echocardiography, espe-
cially during exercise stress, when an inadequate response
to stress, indicative of subclinical cardiac dysfunction
could be revealed. MUGA has been shown to have good
application especially for allowing appropriate treatment
modiﬁcation with good clinical outcome (4). It is how-
ever time consuming, should not be performed frequently
as it involves radionucleide injection and has almost the
same limitations as echo regarding the pathophysiology
of the measured injury.
BNP levels
B-type naturetic protein (BNP) was considered useful
in predicting the risk of developing cardiac disease.
(Studies). Recent data has demonstrated that in TM
patients there is no predictive value with that measure-
ment for heart iron load (23). BNP was only elevated in
patients who had overt cardiac dysfunction and the levels
did not reﬂect the severity of heart failure (90).
Cardiac magnetic resonance imaging
As there was no particular examination giving a real indi-
cation of cardiac risk, the ability to determine cardiac iron
was therefore crucial. Cardiac biopsy is invasive and inac-
curate (91, 92), therefore the ability to assess cardiac iron
non-invasively, reproducibly and accurately, was impera-
tive. CMR has offered that capability and has revolution-
ized the approach to management of TM. A number of
studies have demonstrated the value of CMR in indirect
assessment of cardiac iron overload (T2*) and function
parameters (20, 93–96). Many other centres are instituting
either the same or similar MRI techniques. The results
appear to be comparable using different machines and in
different countries (97). They are reproducible and robust,
provided the T2* method is used and the area measured is
the intraventricular septum (98). The classiﬁcation of
patients is that those with T2* > 25 ms are regarded as
not having cardiac iron (22), though some centres suggest
>20 ms (20, 23). Both from our experience and that of
other centres, it seems that even though T2* of the heart
between 20 and 25 ms may be a grey zone with respect to
iron load, patients with such levels or more are thought
not to have increased risk of developing CCF. Those with
T2* between 10 and 20 ms have mild to moderate cardiac
iron load and those <10 ms are considered to have heavy
cardiac iron load.
Advantages
The major beneﬁt from the use of MRI is that it allows
the comparison of iron load to heart function. It is clear
that cardiac damage is related to the amount of cardiac
iron. MRI provides the ability to determine the predic-
tive value of ferritin, LIC, echo and BNP with respect to
cardiac iron. It can also assess the impact of the patients’
compliance to therapy and their red cell consumption on
cardiac iron. Furthermore with the conﬁdence in the
studies, we can make appropriate treatment modiﬁca-
tions, for each individual patient based on the assessed
cardiac iron load. Finally it allows monitoring of the
effect of the treatment modiﬁcations.
Disadvantages
The disadvantages of CMR are that it is expensive, time
consuming, performed within a claustrophobic environ-
ment, and cannot be used in patients with cardiac
pacemakers, deﬁbrillators or implantable pumps in the
chest. Indwelling portacaths with titanium ports or stents
do not interfere with the study. Also, it is not universally
available.
Heart iron MRI measurements are limited to the
deposited forms of ferritin and haemosiderin that com-
prises the majority of the cellular iron but it cannot mea-
sure the toxic LCI. Despite this, given the fact that a
continuous interaction between the three forms of iron
exists, MRI measurement remains the best method for
estimating potential iron toxicity.
Chelation treatment for prevention of iron induced
heart disease
Chelation treatment today should be guided by MRI
ﬁndings, if the technique is available. We are in a tran-
sient phase of knowledge with the availability of MRI
and new chelating agents. Important questions with
respect to best management to avoid iron induced car-
diac disease remain to be elucidated. Optimal manage-
ment may be clariﬁed from results of different trials and
current ongoing follow up studies from many subgroups
of patients using different regimes.
In the presence of excess cardiac and or hepatic iron,
treatment strategies include increase of the dose and⁄or
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(deferiprone or deferasirox) or to the combination of
deferiprone with desferrioxamine, provided there are no
contraindications to their use (45). With respect to hepatic
iron removal, the efﬁcacy of the two oral chelators is at
least equal to the standard doses of desferrioxamine (99–
101). Recent and ongoing studies have demonstrated that
deferiprone, a small molecule that permeates all tissues, is
more efﬁcient in removing cardiac iron and improving car-
diac function than desferrioxamine (99, 100). Some preli-
minary clinical and laboratory observations with
deferasirox are encouraging with respect to removal of
cardiac iron (102, 103). As yet, there are no studies with
combinations of deferasirox and desferrioxamine so this
therapeutic regime cannot be recommended at this stage.
Renal dysfunction is rare in TM, however, it is important
to note that adequate renal function is essential for the
elimination of the chelators. Chelator adjustment will be
necessary. If the patient has renal failure, it is essential that
aggressive haemodialysis is instituted.
According to the current knowledge and based on the
CMR ﬁndings, the suggested chelation regimes are as
follows:
Acceptable cardiac iron
For patients with T2* greater than 20 ms, the therapeutic
strategy should be continuation of monotherapy with
either desferrioxamine or either of the available oral
chelators (deferiprone and desferasirox) with regular
follow-up. For patients convenience, desferrioxamine
administration may be converted to either of the two
oral chelators.
Mild to moderate cardiac iron loading
T2* values between 10 and 20 ms are considered to
reﬂect a mild to moderately iron loaded myocardium.
Bearing in mind that the patients may be at risk of
developing cardiac problems under stress such as infec-
tions, clearing myocardial tissue from iron seems to be a
rational target. Therefore, combined treatment for these
patients should not be a priori excluded. Patients have
presented with LV dysfunction at levels of T2* of 15 ms,
without any precipitating factors (22). Therefore, if T2*
is £15 ms, combination chelation therapy is recom-
mended (45). However, questions still exist, regarding the
frequency and the amount of desferrioxamine adminis-
tration that is appropriate in a combined regimen. A
dose of 35–40 mg⁄kg⁄d three-four times weekly com-
bined with deferiprone at a dose of 75 mg⁄kg⁄d seems to
be reasonable. In patients with T2* 15–20 ms, mono-
therapy with either deferiprone or deferasirox together
with careful follow up are available options (99, 100).
Patients treated up to the time of the MRI with desferri-
oxamine in this category and who availed themselves of
that treatment satisfactorily, should not be on monother-
apy with that compound, as deferrioxamine was inade-
quate at preventing the iron accumulation in the heart
and may indicate some type of resistance to its efﬁcacy
within that patient.
Heavy cardiac iron load
Patients with T2* <10 ms are considered to have severe
iron overload and this category includes most patients
with reduced LV function. Even those patients with nor-
mal ejection fraction in this category are considered to
be at very high risk of developing cardiac dysfunction.
Thus all patients in this category have a strong indica-
tion for combined chelation treatment. The doses of the
two medications should be similar to those described for
patients with CCF but with the desferrioxamine being
given as a subcutaneous infusion.
Any treatment modiﬁcation should be followed by
close monitoring. Should any serious adverse effect pres-
ent as a consequence of the administration of a particu-
lar chelator, appropriate guidelines as to its continued
use should be followed.
If treatment has ultimately modiﬁed the MRI patient’s
classiﬁcation then, it may be adjusted as discussed above
according to the changes in MRI values.
Guidelines if MRI is not available
In countries where MRI is not available, then all the
patients’ traditional parameters need to be analysed,
(ferritins, liver iron concentrations) as well as ECG and
echocardiogram, taking into account the above discussed
limitations. These may serve as a guide to treatment.
Furthermore, according to knowledge from MRI studies
in countries where follow up of patients occurs, up to
65% of patients have cardiac iron load. In Sardinia,
13% had severe cardiac iron overload (23). In our study
48% of patients have T2* < 15 ms (22). In countries
were patients compliance to treatment is inadequate,
there was poor availability of chelation and⁄or the follow
up was not well organised, the percentage of cardiac iron
loaded patients is likely to be higher. Therefore, for
patients who have never had optimal care, it is very
likely the patients will have cardiac iron load and inten-
sive chelation is the treatment of choice. In patients who
have been poorly chelated, the risk of chelation toxicity
is minimal and would only be likely to occur after pro-
longed therapy, however, it is important to be vigilant
for such complications. MRI is more necessary for those
patients who have had good chelation therapy but who
are at risk of chelation inadequacy with respect to the
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in order to follow the efﬁcacy of the changed chelation
regime.
Conclusions on prevention of heart disease
This formerly catastrophic genetic defect has been revo-
lutionized with the availability of adequate chelation
therapy and more recently with other important
advances.
It remains important, practically, to aim to maintain
low LIC’s and ferritin levels, particularly as the latter are
easily accessible and assessable. Similarly, echocardiogra-
phy should remain a routine tool as it does have some
predictive value and can also be used to monitor patients
in whom intensiﬁcation of chelation therapy has been
instituted.
Cardiac magnetic resonance imaging can be particu-
larly helpful in identifying all TM patients at risk of
developing heart disease by assessing the cardiac iron
load. Chelation therapy can be tailored to remove the
excess heart iron. Attention to patient’s continuous com-
pliance with adequate chelation is mandatory.
The deﬁnite ability to know and reduce cardiac iron as
well as improvement in cardiac function that has been
reported, should certainly lead to even further signiﬁcant
reduction in cardiac mortality and morbidity.
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